Morris, M. F., Silva, I. E. D. P. D., Richardson, G. E., Kao, S. C., Zang, Y., Wang, Q., Li, J., Yu, H. (2025). Safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of HLX301, a bispecific antibody targeting PD-L1 and TIGIT, in patients with advanced solid tumors.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.2647